Nature Medicine November 12, 2026

Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial

Jakob Wirbel, Wael Saber, Michael J. Martens, Ami S. Bhatt et al.

Bottom Line

In a prespecified phase 3 companion study (BMT CTN 1801), gut microbiome diversity at engraftment did not predict non-relapse mortality, though the highly effective post-transplant cyclophosphamide regimen caused more profound early microbiome disruption than standard tacrolimus and methotrexate.

Key Findings

1. No significant association was observed between engraftment microbiome diversity and 1-year non-relapse mortality (P=0.314), failing to meet the primary trial endpoint.
2. Lower baseline (pre-transplant) microbiome diversity was significantly associated with shorter overall survival (P=0.007).
3. On days 14–28 post-HCT, patients receiving PTCy exhibited significantly lower microbiome diversity and lower absolute microbial load compared to those receiving Tac/MTX.
4. Beneficial Clostridia species, notably the bile-acid-modifying Clostridium scindens, and secondary bile-acid metabolism pathways were significantly less prevalent in the PTCy arm following HCT.
5. The presence of secondary bile-acid metabolism pathways correlated with lower chronic GVHD risk primarily in the Tac/MTX cohort, resulting in an incidence similar to the PTCy-based regimen and suggesting that microbiome-immune interactions differ mechanistically by prophylaxis type.

Study Design

Design
RCT (Companion Study)
Open-Label
Sample
304
Patients
Duration
1 yr
Median
Setting
Multicenter, US
Population Adults with hematologic malignancies (primarily AML and MDS) undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation
Intervention Post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF)
Comparator Tacrolimus (Tac) and methotrexate (MTX)
Outcome Association between gut microbiome diversity (Shannon's index) at neutrophil engraftment and non-relapse mortality at 1 year

Study Limitations

• Bile acid metabolic pathways (such as bile salt hydrolase activity) were inferred computationally from metagenomic sequencing rather than directly quantified through metabolomics.
• Differences in non-prophylaxis antibiotic exposure between the treatment arms may partially confound longitudinal microbiome analyses, despite mixed-effect model adjustments.
• Mechanistic associations linking specific taxa, like C. scindens, to GVHD protection are correlative and require functional in vivo validation to establish causality.

Clinical Significance

This study challenges the universal applicability of post-transplant microbiome diversity as a prognostic biomarker for non-relapse mortality, particularly in the era of post-transplant cyclophosphamide (PTCy). It demonstrates that while PTCy provides superior GVHD-free survival, it paradoxically induces a more severe, early disruption of the microbiome and depletes beneficial bile-acid-modifying species. Consequently, future microbiome-targeted therapeutics, such as precision live biotherapeutics, will likely need to be tailored to the specific pharmacological conditioning and prophylaxis regimen used rather than employing a one-size-fits-all approach.

Historical Context

Historically, severe loss of gut microbiome diversity following allogeneic hematopoietic cell transplantation (allo-HCT) has been strongly correlated with increased rates of graft-versus-host disease (GVHD) and higher non-relapse mortality in retrospective cohorts. Concurrently, the landmark BMT CTN 1703 trial (published in 2023) established post-transplant cyclophosphamide (PTCy) as the new standard of care for GVHD prophylaxis in reduced-intensity conditioning, given its superior GVHD-free, relapse-free survival compared to standard tacrolimus and methotrexate (Tac/MTX). The BMT CTN 1801 study was integrated as a prespecified companion trial to prospectively evaluate how these distinctly different pharmacologic regimens affect microbiome dynamics, and whether microbiome diversity retains its prognostic value under modern PTCy-based immunosuppression.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How do the mechanisms of action of high-dose post-transplant cyclophosphamide and standard methotrexate differ regarding their mucosal toxicity in the gastrointestinal tract, and how does this relate to their potential to disrupt the gut microbiome?

Key Response

Cyclophosphamide is a potent alkylating agent that causes widespread DNA cross-linking and severe mucosal injury, whereas methotrexate is an antimetabolite (folate antagonist) with a different toxicity profile. The profound, direct mucosal damage and rapid cell death from high-dose post-transplant cyclophosphamide severely disrupt the intestinal barrier and local immune environment, leading to a more drastic early shift in the microbiome compared to the targeted effects of standard Tacrolimus/Methotrexate.

Resident
Resident

Given that PTCy causes more profound early gut microbiome disruption but is highly effective at preventing GVHD, how should this influence a clinician's index of suspicion for early infectious complications or mucosal-barrier-related issues compared to patients receiving Tac/MTX?

Key Response

Residents must balance the superior GVHD protection of PTCy against its early toxicities. The profound early microbiome disruption and severe mucosal injury suggest patients may be at a temporarily increased risk for bacterial translocation, severe mucositis, or opportunistic enteric infections during the immediate post-transplant period, requiring vigilant clinical monitoring and tailored supportive care.

Fellow
Fellow

Prior observational studies heavily suggested that low gut microbiome diversity at engraftment strongly predicts non-relapse mortality (NRM). How does this phase 3 trial's finding challenge our understanding of microbiome-mediated immune tolerance and its utility as a prognostic marker?

Key Response

This finding breaks the long-standing dogma that a healthy, diverse microbiome at engraftment is universally required to prevent severe GVHD and NRM. It suggests that the immense immunosuppressive efficacy of PTCy overrides the deleterious effects of early microbiome depletion, indicating that in modern regimens, the initial microbiome state may be a byproduct of conditioning/prophylaxis intensity rather than the primary driver of NRM.

Attending
Attending

For years, the transplant community has explored utilizing microbiome diversity metrics as prognostic biomarkers. Based on the BMT CTN 1801 companion study results, how should we re-evaluate the clinical utility of preemptively acting upon microbiome diversity scores at the time of engraftment in PTCy-based transplants?

Key Response

The lack of association between engraftment microbiome diversity and NRM in this randomized trial suggests that microbiome profiling at engraftment should not dictate routine clinical decision-making or justify preemptive, off-protocol interventions (like microbiome therapeutics or fecal transplants) in the context of PTCy-based regimens, allowing attendings to save resources and focus on established clinical parameters.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

Previous observational cohorts established a strong link between low microbiome diversity and NRM, yet this randomized controlled trial found no such prediction. From an epidemiological standpoint, what specific biases in earlier observational studies does this RCT likely expose, and how should this alter the statistical design of future microbiome companion studies?

Key Response

This discrepancy highlights confounding by indication in observational studies, where patients receiving more intense therapies, experiencing early complications, or requiring broad-spectrum antibiotics had both worse microbiomes and higher NRM. The randomization in this trial evenly distributed these unmeasured confounders. Future studies must move beyond single time-point diversity metrics and power for dynamic longitudinal microbiome trajectories while strictly controlling for antibiotic exposure.

Journal Editor
Journal Editor

A major confounder in any multi-center microbiome study is the heterogeneity of empiric antibiotic use across different institutions. As a reviewer evaluating this phase 3 companion study, how would you scrutinize the authors' handling of center-specific prophylactic and empiric antibiotic protocols in their multivariable analysis?

Key Response

Antibiotic exposure is the most dominant driver of microbiome disruption. If the PTCy arm coincidentally received different antibiotics (e.g., due to higher rates of early neutropenic fever), the disruption might be antibiotic-driven rather than PTCy-driven. A rigorous review requires ensuring the statistical models appropriately adjusted as a time-varying covariate for the duration, spectrum, and timing of antibiotic use across the different study arms.

Guideline Committee
Guideline Committee

Current ASTCT and EBMT guidelines increasingly recognize PTCy as a standard-of-care GVHD prophylaxis, yet theoretical concerns about mucosal toxicity and microbiome disruption have persisted. How do the results of BMT CTN 1801 reassure guideline committees regarding the net clinical benefit of PTCy, and does this evidence support upgrading its recommendation strength despite the early microbiome hit?

Key Response

Guidelines weigh overall risks and benefits. This study provides Level 1 evidence that the early profound microbiome disruption caused by PTCy does not translate to worse non-relapse mortality. This reassures committees that the superior GVHD prevention of PTCy far outweighs theoretical risks of microbiome depletion, strongly supporting Grade 1A recommendations for its use in both mismatched and matched allogeneic stem cell transplants without mandating microbiome-protective strategies.

Clinical Landscape

Noteworthy Related Trials

2021

BMT CTN 1301

n = 344 · JCO

Tested

Post-transplantation cyclophosphamide or CD34+ cell selection

Population

Patients with acute leukemia or myelodysplasia undergoing myeloablative HCT

Comparator

Standard tacrolimus and methotrexate

Endpoint

GVHD-free, relapse-free survival

Key result: PTCy resulted in lower rates of chronic GVHD without increasing relapse risk compared to standard tacrolimus and methotrexate.
2021

ABA2 Trial

n = 142 · JCO

Tested

Abatacept plus standard calcineurin inhibitor and methotrexate

Population

Patients undergoing unrelated donor allogeneic hematopoietic stem cell transplantation

Comparator

Placebo plus standard calcineurin inhibitor and methotrexate

Endpoint

Grade II-IV acute GVHD-free survival at day 100

Key result: The addition of abatacept to standard prophylaxis significantly reduced the incidence of severe acute GVHD and improved overall survival.
2023

BMT CTN 1703

n = 431 · NEJM

Tested

Post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil

Population

Adults undergoing reduced-intensity allogeneic hematopoietic stem-cell transplantation

Comparator

Tacrolimus and methotrexate

Endpoint

GVHD-free, relapse-free survival at 1 year

Key result: Post-transplantation cyclophosphamide significantly improved 1-year GVHD-free, relapse-free survival compared to standard prophylaxis.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑